Porphycene compounds for photodynamic therapy

US5262401A · kind A · utility

Assignee

• Cytopharm, Inc. · US

Inventors

• Emanuel Vogel · Cologne, DE
• Clemens Richert · Munich, DE
• Thomas Benninghaus · Cologne, DE
• Martin Muller · Berlin, DE
• Alexander D. Cross · Atherton, US

Key dates

• Filing date: Apr 29, 1992
• Grant date: Nov 16, 1993
• Expiry date: Apr 29, 2012

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K41/0057
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A porphycene having the structure ##STR1## wherein each R.sup.1 is, independently, (a) --(CH.sub.2).sub.n --X, where n= 1-4, X is OR.sup.2 and R.sup.2 is C.sub.1-6 alkyl, aralkyl or aryl; CN; OH; OSO.sub.2 R.sup.2 ; NH.sub.2 ; NHR.sup.2 ; NR.sup.2.sub.2 ; SH; SR.sup.2 ; S(O).sub.1-2 R.sup.2 ; COOH; CO.sub.2 R.sup.2 ; C(O)NH.sub.2 ; C(O)NHR.sup.2 ; C(O)NR.sup.2.sub.2 ; halogen; or CHO; PA0 (b) --(CH.sub.2).sub.m CH.dbd.CH.sub.2 where m is 0-2; or PA0 (c) --(CH.sub.2).sub.n --O--G where G is a mono- or oligosaccharide; PA0 (d) --(CH.sub.2).sub.2n --X, where X is an amino acid, oligopeptide covalently bonded by an ether-, ester- or amine-bond or --Y--(CH.sub.2).sub.n -porphycene.sup.2 (porphycene.sup.2 being a compound of the same structure and Y is a direct bond; --O--; or --CH.dbd.CH.sub.2); or PA0 (e) where one, two or three of the substituents R.sup.1 are C.sub.1-6 alkyl or aryl and the remaining substituents are as above under (a)-(d), and salts and metal complexes thereof. The porphycene compounds and pharmaceutical compositions containing the compounds are useful in photodynamic therapy treatment of tumors and psoriasis.